Since induced pluripotent stem cells (iPSCs) were first produced in 2006 from mouse cells and in 2007 from human cells, scientists have recognized the incredible potential of the cell type, including their utility in drug and toxicology screening, disease modeling, and cellular therapy applications ranging from gene correction, to whole tissue regeneration, individualized medicine, and more. Given the financial potential of the cell type, it is important to have strategies for accessing key individuals, events, and iPSC facilities.
[Read more…]
My Story: Founder of a Stem Cell Market Research Firm and a Stem Cell Patient
For nearly two decades, I have studied stem cells, including technology and research advances, as well as market trends. I have been fascinated with them for most of my adult life, founding BioInformant as the first and only market research firm to specialize in the stem cell industry.
As a result of this decision, I have had the honor of serving thousands clients from across the stem cell industry and been interviewed by the Wall Street Journal, Los Angeles Business Journal, and Vogue Magazine.
However, it was only recently that I experienced the power of stem cells to impact my own life and health.
Price-per-Click Costs Reveal Current Levels of Market Competition for iPS Cells
Purpose of Induced Pluripotent Stem Cell (iPSC) Marketing Analysis
An important area to consider for purposes of quantifying and assessing conditions within the iPSC market is marketing costs.
 Because Google now controls over 70% of online searches, Google Adwords is the single best resource available for analyzing both marketing costs and online search behavior within the induced pluripotent stem cell (iPSC) market.  Specifically, this post considers marketing costs for search terms related to iPSCs, using the Google Adwords tool.
[Read more…]
Mesenchymal Stem Cell Industry News Round Up | July 2015
The mesenchymal stem cell industry is well-known for its shifting dynamics, including new alliances, new research advances and innovations. Every month there are major new events that affect market participants.
While it may be possible to stay informed about mesenchymal stem cell industry news in your region, it can be more difficult to track changes on a global scale. For that reason, the following is a summary of significant mesenchymal stem cell industry events for July 2015.
3 Eerie Similarities between the Acquisition of Cord Blood Registry® (CBR) and ViaCord
Cord Blood Registry® (CBR) recently made headlines by announcing that it had entered into a definitive agreement to be acquired by AMAG Pharmaceuticals for $700M. While the announcement was new, there were aspects of the deal that seemed eerily familiar.
[Read more…]
- « Previous Page
- 1
- …
- 326
- 327
- 328
- 329
- 330
- …
- 334
- Next Page »